Clinical efficacy and safety of external radiotherapy combined with sorafenib in the treatment of hepatocellular carcinoma: a systematic review and meta-analysis |
| |
| Authors: | Jiali Chen Kun He Yunwei Han Lu Guo Ke Su Zhenying Wu |
| |
| Affiliation: | 1. Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000 Sichuan, China;2. Clinical Research Institute, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000 Sichuan, China |
| |
| Abstract: | Introduction and ObjectivesBoth external radiotherapy and sorafenib are promising treatments for hepatocellular carcinoma (HCC). Nevertheless, the combined treatment of external radiotherapy and sorafenib has not been widely applied clinically due to potentially adverse effects. This meta-analysis aimed to evaluate the clinical efficacy and safety of external radiotherapy combined with sorafenib in the treatment of HCC.MethodsPubmed, MEDLINE, EMBASE, Cochrane Library, and Web of Science databases were searched. The primary and secondary observation endpoints were the end of survival and incidence of adverse events, respectively. 11 studies involving 664 patients were included in this meta-analysis.ResultsThe results demonstrated that median overall survival (mOS) and median progression-free survival (mPFS) of the external radiotherapy combined with sorafenib (RS) group were 19.45 months and 8.20 months. The one- and two-year survival rates were 0.65 (95%CI: 0.55–0.76) and 0.40 (95%CI: 0.24–0.56). The incidence of adverse events was 0.34 (95%CI: 0.25–0.44).ConclusionsThe findings demonstrated that the survival of the RS group was significantly improved and few severe adverse events were observed. Hence, it can be concluded that external radiotherapy combined with sorafenib is a safe, effective, and promising therapeutic option for HCC. |
| |
| Keywords: | HCC" },{" #name" :" keyword" ," $" :{" id" :" pc_anlb7JzGi4" }," $$" :[{" #name" :" text" ," _" :" hepatocellular carcinoma mOS" },{" #name" :" keyword" ," $" :{" id" :" pc_bVz3AsV6kt" }," $$" :[{" #name" :" text" ," _" :" median overall survival mPFS" },{" #name" :" keyword" ," $" :{" id" :" pc_A2IrFfTkn7" }," $$" :[{" #name" :" text" ," _" :" median progression-free survival RS" },{" #name" :" keyword" ," $" :{" id" :" pc_eRnuMIHqCJ" }," $$" :[{" #name" :" text" ," _" :" external radiotherapy combined with sorafenib HBV" },{" #name" :" keyword" ," $" :{" id" :" pc_ye0OzDqbRx" }," $$" :[{" #name" :" text" ," _" :" hepatitis B virus HCV" },{" #name" :" keyword" ," $" :{" id" :" pc_fH2UW10jdB" }," $$" :[{" #name" :" text" ," _" :" hepatitis C virus OLT" },{" #name" :" keyword" ," $" :{" id" :" pc_YOkT3PCxrG" }," $$" :[{" #name" :" text" ," _" :" orthotopic liver transplantation MSR" },{" #name" :" keyword" ," $" :{" id" :" pc_gIkFsgXwyj" }," $$" :[{" #name" :" text" ," _" :" median survival ratio OR" },{" #name" :" keyword" ," $" :{" id" :" pc_ypSbEaAXe2" }," $$" :[{" #name" :" text" ," _" :" odd ratio ORR" },{" #name" :" keyword" ," $" :{" id" :" pc_80dbGNNsik" }," $$" :[{" #name" :" text" ," _" :" objective remission rate DCR" },{" #name" :" keyword" ," $" :{" id" :" pc_WNa3J64ws6" }," $$" :[{" #name" :" text" ," _" :" disease control rate 3D-CRT" },{" #name" :" keyword" ," $" :{" id" :" pc_ymkxHxBsVp" }," $$" :[{" #name" :" text" ," _" :" 3-dimensional conformal radiotherapy IMRT" },{" #name" :" keyword" ," $" :{" id" :" pc_FV3ReMaQ2t" }," $$" :[{" #name" :" text" ," _" :" intensity-modulated radiotherapy SBRT" },{" #name" :" keyword" ," $" :{" id" :" pc_V2xD1QOavc" }," $$" :[{" #name" :" text" ," _" :" stereotactic body radiotherapy |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
